secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2026-08-21T13:10:29+00:00
Accession:  0001193125-26-360059
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf to merge with Ambros in reverse merger; Ambros valued at $500M, PIPE of $150M
--------------------------------------------------------------------------------

- Merger Sub to merge into Ambros; Ambros stockholders to own ~71.7% of combined company; Werewolf pre-merger holders ~6.8%.
- Concurrent PIPE financing of $150M from qualified investors; proceeds condition to close; implies Werewolf valuation $47.5M.
- Werewolf stockholders get CVRs for legacy WTX-124 and WTX-330 assets; no assurance of payments.
- Termination fees: $20M payable by Ambros in certain circumstances; $1.9M payable by Werewolf.
- Transaction requires stockholder approvals, S-4 filing, Nasdaq listing, and net cash condition; expected close not specified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312526360059/0001193125-26-360059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312526360059/d102535d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-360059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer